Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Exercise and quality of life in women with multiple sclerosis.
On dihydroorotate dehydrogenases, their inhibitors and uses.
Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study.
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Corticosteroids for treating optic neuritis.
Sexual dysfunction ın multiple sclerosis: Gender differences.
T cells become licensed in the lung to enter the central nervous system.
An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis.
Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
ATX-MS-1467 - Positive Immunological data in Multiple Sclerosis: Final Phase I/IIa data shows safety and tolerability, plus efficacy
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Embryonic stem cell lines derived from human blastocysts.
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
Olive oil phenols and neuroprotection.
Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis.
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past.
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.
Focused suggestion with somatic anchoring technique: rapid self-hypnosis for pain management.
Vivitrol dosing and administration
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Pages
« first
‹ previous
…
115
116
117
118
119
120
121
122
123
…
next ›
last »